Drug Search
Search the NC formulary database by brand name, generic name, drug class, or active ingredient. Search tips
Informational only — Formulary data may be inaccurate or outdated. Always verify with official plan documents, your pharmacy, or your clinician before acting.
29 results for "GLP-1"
Page 1 of 2| Drug Name | Generic Name | Strength | Form | Plans Covering | Actions |
|---|---|---|---|---|---|
|
Bydureon
Brand for exenatide GLP-1 Receptor Agonist Also: exenatide |
exenatide | 1.9975 MG | Auto-Injector | 13 plans | Details |
|
Byetta
Brand for exenatide Hypoglycemics - Injectable — Rapid Acting Insulin Also: Byetta 5 Mcg Dose Pen Injector, Byetta 10 Mcg Dose Pen Injector |
exenatide | 10 Mcg | Pen Injector | 21 plans | Details |
|
GLP-1 Receptor Agonists and Combinations indicated for the treatment of Diabetes
Hypoglycemics - Injectable — Rapid Acting Insulin |
— | — | — | 1 plan | Details |
|
Mounjaro
Brand for tirzepatide ANTIDIABETICS Also: tirzepatide, Mounjaro 2.5 Mg/0.5 Ml Pen, Mounjaro 5 Mg/0.5 Ml Pen, Mounjaro 7.5 Mg/0.5 Ml Pen, Mounjaro 10 Mg/0.5 Ml Pen, Mounjaro 12.5 Mg/0.5 Ml Pen, Mounjaro 15 Mg/0.5 Ml Pen, MOUNJARO SOAJ 2.5MG/0.5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML, 15MG/0.5ML |
tirzepatide | 2.5MG/0.5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML, 15MG/0.5ML | Pen Injector | 219 plans | Details |
|
Mounjaro Subcutaneous
GLP-1 Receptor Agonist Also: Mounjaro Subcutaneous Solution Pen-injector, Mounjaro Subcutaneous Solution Auto-injector |
— | 12.5 MG/0.5ML | Solution | 149 plans | Details |
|
Ozempic
Brand for semaglutide ANTIDIABETICS Also: 0.25 MG,, semaglutide, Ozempic 0.25-0.5 Mg/Dose Pen Injector, Ozempic 1 Mg/Dose (4 Mg/3 Ml) Pen Injector, Ozempic 2 Mg/Dose (8 Mg/3 Ml) Pen Injector |
semaglutide | 2.01 MG, 2.04 MG, 4.02 MG, 8.04 MG | Pen Injector | 246 plans | Details |
|
Ozempic (0.25 or
GLP-1 Receptor Agonist |
— | 0.5 MG | — | 150 plans | Details |
|
Ozempic (2 MG/DOSE) Subcutaneous
GLP-1 Receptor Agonist Also: Ozempic (2 MG/DOSE) Subcutaneous Solution Pen-injector |
— | 2 MG | Solution | 150 plans | Details |
|
Qsymia
Brand for phentermine/Topiramate ANOREXIANTS NON-AMPHETAMINE Also: QSYMIA CAP 3.75-23, QSYMIA CAP 7.5-46MG, QSYMIA CAP 11.25-69, QSYMIA CAP 15-92MG |
phentermine/Topiramate | 46MG | Capsule | 5 plans | Details |
|
Rybelsus
Brand for semaglutide ANTIDIABETICS Also: RYBELSUS TABS 1.5MG, 3MG, 4MG, 7MG, 9MG, 14MG, semaglutide, Rybelsus 1.5 Mg Tablet, Rybelsus 3 Mg Tablet, Rybelsus 4 Mg Tablet, Rybelsus 7 Mg Tablet, Rybelsus 9 Mg Tablet, Rybelsus 14 Mg Tablet, RYBELSUS TABS 3MG, 7MG, 14MG, Rybelsus Oral Tablet |
semaglutide | 1.5MG, 3MG, 4MG, 7MG, 9MG, 14MG | Tablet | 252 plans | Details |
|
Rybelsus (Formulation R2)
GLP-1 Receptor Agonist Also: Rybelsus (Formulation R2) Oral Tablet |
— | 1.5 MG | Tablet | 10 plans | Details |
|
Saxenda
Brand for liraglutide Weight Management Agents — GLP-1 Receptor Agonists indicated for the treatment of obesity (Incretin Mimemetics) Also: liraglutide |
liraglutide | 18 MG | Pen Injector | 1 plan | Details |
|
Trulicity Subcutaneous
GLP-1 Receptor Agonist Also: Trulicity Subcutaneous Solution Pen-injector, Trulicity Subcutaneous Solution Auto-injector |
— | 0.75 MG/0.5ML | Solution | 149 plans | Details |
|
Victoza
Brand for liraglutide Hypoglycemics - Injectable — Rapid Acting Insulin Also: liraglutide |
liraglutide | 18 MG | Pen Injector | 10 plans | Details |
|
Victoza Subcutaneous
GLP-1 Receptor Agonist Also: Victoza Subcutaneous Solution Pen-injector |
— | 18 MG/3ML | Solution | 7 plans | Details |
|
Wegovy
Brand for semaglutide Weight Management Agents — GLP-1 Receptor Agonists indicated for the treatment of obesity (Incretin Mimemetics) Also: semaglutide, WEGOVY SOAJ .25MG/0.5ML, .5MG/0.5ML, 1MG/0.5ML, 1.7MG/0.75ML, 2.4MG/0.75ML, Wegovy Pen, WEGOVY SOAJ .25MG/0.5ML, .5MG/0.5ML, 1MG/0.5ML, 1.7MG/0.75ML, 2.4MG/0.75ML; TABS 1.5MG, 4MG, 9MG, 25MG |
semaglutide | 0.25 MG, 0.5 MG, 1 MG, 1.7025 MG, 2.4 MG | Pen Injector | 6 plans | Details |
|
Weight Management
Brand for Non-Incretin Mimetics Weight Management Agents — GLP-1 Receptor Agonists indicated for the treatment of obesity (Incretin Mimemetics) Also: Non-Incretin Mimetics |
Non-Incretin Mimetics | — | — | 1 plan | Details |
|
Xenical
Brand for orlistat Weight Management Agents — GLP-1 Receptor Agonists indicated for the treatment of obesity (Incretin Mimemetics) Also: orlistat, XENICAL CAPS 120MG |
orlistat | 120MG | Capsule | 3 plans | Details |
|
Zepbound
Brand for tirzepatide Weight Management Agents — GLP-1 Receptor Agonists indicated for the treatment of obesity (Incretin Mimemetics) Also: tirzepatide, Zepbound Pen |
tirzepatide | 2.5 MG, 5 MG, 7.5 MG, 10 MG, 12.5 MG, 15 MG | Pen Injector | 4 plans | Details |
|
benzphetamine
Weight Management Agents — GLP-1 Receptor Agonists indicated for the treatment of obesity (Incretin Mimemetics) |
— | — | Tablet | 1 plan | Details |
|
diethylpropion tablet
Weight Management Agents — GLP-1 Receptor Agonists indicated for the treatment of obesity (Incretin Mimemetics) |
— | — | Extended Release Tablet | 1 plan | Details |
|
exenatide
Brand for Bydureon Hypoglycemics - Injectable — Rapid Acting Insulin Also: Byetta, BYETTA |
Bydureon | 10 mcg/0.04 mL per dose (250 mcg/mL) 2.4 mL, 5 mcg/0.02 mL per dose (250 mcg/mL) 1.2 mL | Pen Injector | 23 plans | Details |
|
liraglutide
Brand for Saxenda Hypoglycemics - Injectable — Rapid Acting Insulin Also: Victoza, liraglutide Pen/5-pak, generic Saxenda, SAXENDA, VICTOZA 3-PAK, VICTOZA 2-PAK |
Saxenda | 0.6 mg/0.1 mL (18 mg/3 mL), 3 mg/0.5 mL (18 mg/3 mL) | Pen Injector | 91 plans | Details |
|
orlistat
Brand for Xenical Weight Management Agents — GLP-1 Receptor Agonists indicated for the treatment of obesity (Incretin Mimemetics) Also: Xenical, orlistat caps 120mg, XENICAL |
Xenical | 100 %, 120 mg | Capsule | 8 plans | Details |
|
phendimetrazine tablet
Weight Management Agents — GLP-1 Receptor Agonists indicated for the treatment of obesity (Incretin Mimemetics) |
— | — | Extended Release Capsule | 1 plan | Details |